ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN
But 'Unique Side Effects' A Concern
Executive Summary
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
AskBio Declares Independence After Bayer Acquisition
The gene therapy specialist's CEO Sheila Mikhail tells Scrip she is excited to be getting access to the German group's late-stage clinical and operational expertise while keeping AskBio's entrepreneurial culture and carrying on as an autonomous company on an arm’s-length basis.
Bayer Boosts Gene Therapy Presence With AskBio Buy
After buying BlueRock Therapeutics outright last year, the Leverkusen-headquartered group has put down $2bn up front to acquire another cell and gene therapy specialist in Asklepios BioPharmaceutical.
Need a specific report? 1000+ reports available
Buy Reports